Trials / Active Not Recruiting
Active Not RecruitingNCT05983133
A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors
A Phase 1 Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 68 (actual)
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will test the safety of a drug called PF-08046052/SGN-EGFRd2 in participants with advanced solid tumors. It will also study the side effects of this drug. A side effect is anything a drug does to the body besides treating the disease. Participants will have cancer that cannot be removed (unresectable) or has spread through the body (metastatic). This study will have three parts. Parts A and B of the study will find out how much PF-08046052/SGN-EGFRd2 should be given to participants. Part C will use the dose found in parts A and B to find out how safe PF-08046052/SGN-EGFRd2 is and if it works to treat solid tumor cancers.
Conditions
- Colorectal Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Squamous Cell Carcinoma of the Head and Neck
- Pancreatic Ductal Adenocarcinoma
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PF-08046052 | Given into the vein (IV; intravenously) |
Timeline
- Start date
- 2023-11-14
- Primary completion
- 2026-08-14
- Completion
- 2026-08-14
- First posted
- 2023-08-09
- Last updated
- 2026-04-07
Locations
24 sites across 2 countries: United States, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05983133. Inclusion in this directory is not an endorsement.